StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a note issued to investors on Friday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Up 6.1 %

Shares of NYSE CVM opened at $0.42 on Friday. CEL-SCI has a 12-month low of $0.36 and a 12-month high of $3.08. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The firm has a market cap of $30.76 million, a PE ratio of -0.81 and a beta of 0.65. The company’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.89.

Institutional Trading of CEL-SCI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Calton & Associates Inc. purchased a new stake in CEL-SCI in the 3rd quarter valued at about $50,000. Plotkin Financial Advisors LLC bought a new position in shares of CEL-SCI in the third quarter valued at approximately $98,000. Renaissance Technologies LLC increased its position in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the period. 12.08% of the stock is owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.